Table 1.

Results from several studies conducted since 2000 on the expression of ABCG2 in a variety of solid tumour and leukaemia samples

Samples tested	Results	Method	Reference
43 breast cancer tumours	Uniformly low levels	RT-PCR	Kanzaki et al. (2001)
52 breast cancer tumours	ABCG2 not detected	IHC	Faneyte et al. (2002)
150 variable solid tumours	Frequent expression in astrointestinal adenocarcinomas, endometrial and lung carcinoma and myeloma	IHC	Diestra et al. (2002)
20 AML samples	Variable expression but high in seven samples	RT-PCR	Ross et al. (2000)
20 AML samples	Variable expression	IHC	Sargent et al. (2001)
59 childhood AML samples	High levels detected at relapse	RT-PCR	Steinbach et al. (2002)
20 paired AML samples	Increased expression in relapsed disease	RT-PCR	Van Den Heuvel-Eibrink et al. (2002)
20 paired AML samples	No correlation with relapsed disease	IHC	Van Der Kolk et al. (2002)
40 AML samples	Low levels of expression	RT-PCR	Abbott et al. (2002)
67 childhood ALL samples	ABCG2 of no prognostic significance	RT-PCR	Sauerbrey et al. (2002)
21 AML samples	ABCG2 expression correlated with in vitro flavopiridol toxicity	RT-PCR	Nakanishi et al. (2003b)

Abbreviations: ALL, acute lymphoid leukaemia; AML, acute myeloid leukaemia; IHC, immunohistochemistry; RT-PCR, reverse transcriptase-polymerase chain reaction.